Lazarus
04-18-2007, 06:50 AM
Multiple sclerosis: novel therapies set to increase market value
16th April 2007
An exciting late-stage pipeline is set to dramatically shake up the multiple sclerosis (MS) market, and the value of this sector is forecast to more than double from 2006 to reach $10.7 billion in 2016. Datamonitor predicts Novartis will become a major player in the MS market, with fingolimod seven major market sales forecast to reach $1.4 billion by 2016. Only two candidates are targeting underserved primary progressive and secondary progressive patients in the current late stage pipeline, namely Biogen Idec's Rituxan and BioMS's MBP-8298. If Rituxan and MBP-8298 launch, then strong uptake can be expected and seven major market sales are forecasted to reach $633 million and $479 million in 2016, respectively.
Source: Datamonitor, Pipeline Insight: Multiple Sclerosis - The oral revolution
16th April 2007
An exciting late-stage pipeline is set to dramatically shake up the multiple sclerosis (MS) market, and the value of this sector is forecast to more than double from 2006 to reach $10.7 billion in 2016. Datamonitor predicts Novartis will become a major player in the MS market, with fingolimod seven major market sales forecast to reach $1.4 billion by 2016. Only two candidates are targeting underserved primary progressive and secondary progressive patients in the current late stage pipeline, namely Biogen Idec's Rituxan and BioMS's MBP-8298. If Rituxan and MBP-8298 launch, then strong uptake can be expected and seven major market sales are forecasted to reach $633 million and $479 million in 2016, respectively.
Source: Datamonitor, Pipeline Insight: Multiple Sclerosis - The oral revolution